Kingston Lee, Bergare Jonas, Lönn Hans, Ericsson Cecilia, Grönberg Gunnar, Chen Song, Elmore Charles S
Isotope Chemistry, Pharmaceutical Sciences iMED, AstraZeneca Pharmaceuticals AB, Mölndal, Sweden.
Medicinal Chemistry, Respiratory, Inflammation, and Autoimmune iMED, AstraZeneca Pharmaceuticals AB, Mölndal, Sweden.
J Labelled Comp Radiopharm. 2017 May 30;60(6):294-301. doi: 10.1002/jlcr.3502.
In support of the development of a new treatment for COPD, 2 C-14 labeled compounds were required for in vitro animal studies. The synthesis of nitrile [ C]-1 was completed in 3 steps from C-14 labeled 4-bromobenzonitrile in accord with the previously developed medicinal chemistry route. The second compound, 2, did not possess an arylnitrile as did 1, which made the synthetic design more complex. An advanced, unlabeled benzotriazole containing intermediate, 10, was synthesized in low yield over 3 steps and was subsequently reacted with K CN to give a mixture of diastereomers 12. Separation of the diastereomers followed by deprotection afforded [ C]-2 in a 13% radiochemical yield.
为支持慢性阻塞性肺疾病(COPD)新疗法的开发,体外动物研究需要两种C-14标记的化合物。腈类化合物[C]-1由C-14标记的4-溴苯腈按照先前开发的药物化学路线分三步合成完成。第二种化合物2不像化合物1那样含有芳基腈,这使得合成设计更加复杂。一种先进的、未标记的含苯并三唑中间体10经三步以低产率合成,随后与KCN反应得到非对映异构体12的混合物。分离非对映异构体后进行脱保护,得到放射化学产率为13%的[C]-2。